Lemborexant 5 mg + Control (placebo) group
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Delirium - Postoperative
Conditions
Delirium - Postoperative, Cardiac Surgery, Cardiac Surgery Subjects, Orexin Antagonist, Feasibility Studies, Sleep, In-hospital Mortality
Trial Timeline
May 1, 2025 → Apr 30, 2027
NCT ID
NCT06648681About Lemborexant 5 mg + Control (placebo) group
Lemborexant 5 mg + Control (placebo) group is a phase 2 stage product being developed by Eisai for Delirium - Postoperative. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06648681. Target conditions include Delirium - Postoperative, Cardiac Surgery, Cardiac Surgery Subjects.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06648681 | Phase 2 | Recruiting |
Competing Products
17 competing products in Delirium - Postoperative
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Suvorexant + Placebo | Merck | Phase 3 | 77 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 52 |
| Rivastigmine + Placebo | Novartis | Approved | 85 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 77 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 77 |
| Rivastigmine Patch | Novartis | Approved | 85 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Parecoxib | Pfizer | Approved | 84 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Pregabalin | Pfizer | Phase 3 | 76 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 76 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 64 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 82 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 74 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 77 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 44 |